---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-003611"
form_type: "8-K"
ticker: "TVGN"
cik: "0001860871"
company_name: "Tevogen Bio Holdings Inc."
filed_at: "2024-01-24T23:59:59+00:00"
generated_at: "2026-06-06T19:28:07.337340+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Semper Paratus shifts combined Tevogen Bio listing target to Nasdaq from NYSE American

## Summary
- Parties agreed to seek Nasdaq listing for New Tevogen common stock and public warrants instead of NYSE American.
- Prospectus Supplement filed on Jan 24, 2024 to revise prior proxy statement/prospectus.
- Shareholder meeting to vote on business combination with Tevogen Bio remains scheduled for Jan 29, 2024.
- Semper Paratus (LGST, LGSTW) will redomesticate to Delaware and rename to Tevogen Bio Holdings Inc. upon closing.
- Tevogen Bio is a clinical-stage immunotherapy company with wholly owned IP including three granted patents.

## SEC filing metadata
- accession: 0001493152-24-003611
- form_type: 8-K
- ticker: TVGN
- cik: 0001860871
- company_name: Tevogen Bio Holdings Inc.
- filed_at: 2024-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860871/000149315224003611/0001493152-24-003611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860871/000149315224003611/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-003611
- JSON: https://secwatch.observer/filing/0001493152-24-003611.json
- Plain text: https://secwatch.observer/filing/0001493152-24-003611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.